Categories
Anticancer Drugs Binimetinib Medicine Oncology Pharmacology Physiotherapy

Binimetinib (Mechanism of Action)

In this article we will discuss Binimetinib (Mechanism of Action)

In this article, we will discuss Binimetinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models. Binimetinib and encorafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug alone, coadministration of encorafenib and binimetinib resulted in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. Additionally, the combination of binimetinib and encorafenib delayed the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared to either drug alone.

Pharmacodynamics

Cardiac Electrophysiology
Following Binimetinib 45 mg twice daily, no clinically meaningful QT prolongation was observed.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.